Amsterdam, 2 - 3 March 2027
Schedule
Create your personal agenda –check the favourite icon
Mar 28:55
Conference pass
Chair's opening remarks
Keynotes
Mar 29:00
Conference pass
Implications of policy changes on market access
Keynotes
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Mar 29:40
Conference pass
Keynote panel: The future of European JCA: From Assessments to National implementation
Keynotes
Focus: Regional policy, HTA alignment, regulatory mechanics, and European market readiness.
What are the early takeaways from the initial JCA experiences, and what operational bottlenecks are HTA bodies currently facing?
How will unified European clinical assessments practically translate into national pricing, reimbursement, and economic decisions?
Where can Member States realistically harmonize their processes, and where will national differences remain?
How can the JCA framework be optimized to create a more predictable landscape for developers while accelerating equitable patient access across Europe
Anne Willemsen, Chair JCA Subgroup, Zorginstituut Nederland
Fabienne Bartoli, Inspector General, French National Authority for Health
Thomas Müller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Antonella Cardone, CEO, Cancer Patients Europe
Rimma Berenstein, Deputy Head, Pharmaceuticals Department, G-BA
Mar 210:20
Conference pass
Keynote: Reframing evidence planning for rare diseases in the JCA era - TBC
Keynotes
Session led by: 
Mar 210:40
Conference pass
Keynote: Access by design: Embedding access into core development decisions - TBC
Keynotes
Session led by: 
Mar 212:15
Conference pass
Chair's opening remarks
Track 1 (Market Access)
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Track 1
Mar 212:15
Conference pass
Chair's opening remarks
Track 7 (Rare Diseases)
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Mar 212:15
Conference pass
Chair's opening remarks
Track 8 (Artificial Intelligence & Data)
Session led by: 
Mar 212:15
Conference pass
Chair's opening remarks
Track 9 (HEOR)
Caroline van der Meijden, Director, iMTA
Mar 212:15
Conference pass
Chair's opening remarks
Track 10 (Sustainable Access & Policy)
Mar 212:15
Conference pass
Chair's opening remarks
Track 6 (Reimbursement)
Adam Gordois, Director, Value Demonstration & HEOR, BioCryst Pharmaceuticals
TRACK 6
Mar 212:20
Conference pass
Actionable Frameworks for Rapid Market Access Planning
Track 1 (Market Access)
Session led by: 
Mar 212:20
Conference pass
AI will decide who gets access: why drug contracting is becoming pharma’s most strategic capability - TBC
Track 6 (Reimbursement)
Session led by: 
Mar 212:20
Conference pass
Anchoring evidence-based decisions in a volatile policy landscape: strategic considerations for EU HTAR - TBC
Track 5 (Real World Evidence & Data)
Session led by: 
Mar 212:20
Conference pass
Clearing the fog: A practical guide to EUHTA JCA & expected Country P&R Processes - TBC
Track 9 (HEOR)
Session led by: 
Mar 212:20
Conference pass
From JSC to HTA: early decisions that shape price and access success
Track 2 (HTA)
Session led by: 
Mar 212:20
Conference pass
How US MFN policies are reshaping global pricing paradigms - TBC
Track 3 (Pricing)
Session led by: 
Mar 212:20
Conference pass
Human-in-the-Loop, Generative AI for Joint Clinical Assessment: From PICO Simulations and Living Systematic Literature Reviews to Submission ready JCA Dossiers
Track 8 (Artificial Intelligence & Data)
Session led by: 
Mar 212:20
Conference pass
Most favoured nations, least favoured patients? How US pricing policy could reshape global health equity - TBC
Track 10 (Sustainable Access & Policy)
Session led by: 
Mar 212:20
Conference pass
Quantifying patient flow and costs in rare disease – Benefits for all - TBC
Track 7 (Rare Diseases)
Session led by: 
Mar 212:40
Conference pass
Critical Medicines Act and Recent Policy Changes
Track 10 (Sustainable Access & Policy)
Thomas Müller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Mar 212:40
Conference pass
Navigating Market Access & Joint Clinical Assessment (JCA)
Track 1 (Market Access)
Lotte Steuten, Deputy CEO, Office of Health Economics
Mar 212:40
Conference pass
Rare disease access under uncertainty
Track 7 (Rare Diseases)
Emanuele Marsili, Global Access Lead, CSL
Mar 212:40
Conference pass
Real World Evidence to Demonstrate Value in Mental Health Treatments
Track 5 (Real World Evidence & Data)
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Mar 212:40
Conference pass
Results from CAPRICORD - Poland HTA and Patient Involvement - TBC
Track 2 (HTA)
Magdalena Rdzanek, Consultant, AOTMiT
Mar 212:40
Conference pass
Sustainability in reimbursement decisions
Track 6 (Reimbursement)
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Mar 212:40
Conference pass
The Role of AI in HTA: Perspectives from the HTAi AI & Data Interest Group
Track 2 (HTA)
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Mar 212:40
Conference pass
Upskilling International Access Teams via AI Simulations - TBC
Track 8 (Artificial Intelligence & Data)
Mar 212:40
Conference pass
When Geopolitics Sets the Price: Rethinking HTA’s Value Lens to Sustain Pharmaceutical Innovation in Europe
Track 3 (Pricing)
Jose Diaz, Global Health Systems Economics & Value of Innovation, BMS
Mar 213:00
Conference pass
Beyond advocacy: a multi-stakeholder panel on patient-informed HTA & economic models - TBC
Track 7 (Rare Diseases)
Session led by: 
Mar 213:00
Conference pass
Designing Reimbursement Frameworks That Match Evolving Payer Thresholds - TBC
Track 6 (Reimbursement)
Session led by: 
Mar 213:00
Conference pass
From tools to orchestration: how agentic systems will boost efficiency in P&MA - TBC
Track 8 (Artificial Intelligence & Data)
Session led by: 
Mar 213:00
Conference pass
Policy, pricing, and power shifts: how EU, UK, and global policies are reshaping pharma market access - TBC
Track 1 (Market Access)
Session led by: 
Mar 213:00
Conference pass
Syncing Local Regulatory Compliance with Global Launch Timelines -TBC
Track 4 (Pre-launch Success)
Session led by: 
Mar 213:20
Conference pass
AI, Avatars, and Access: Revolutionizing Patient Engagement and Real-World Evidence
Track 8 (Artificial Intelligence & Data)
Mar 213:20
Conference pass
Improving global accessto medicines
Track 1 (Market Access)
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Mar 213:20
Conference pass
Mind the Gap: evidence requirements for regulatory, evaluation and adoption - TBC
Track 2 (HTA)
Brad Groves, Director, NICE Advice, National Institute for Health & Care Excellence (NICE)
Mar 213:20
Conference pass
Novel types of evidence: can they support reliable HTA decisions?
Track 5 (Real World Evidence & Data)
Steve Sharp, Scientific Advisor, National Institute for Health and Care Excellence
Track 5
Mar 213:20
Conference pass
Reimbursement in China: latest updates
Track 6 (Reimbursement)
Eric Bouteiller, Author & Adjunct Professor, China Europe International Business School (CEIBS)
Track 6
Mar 213:20
Conference pass
Rethinking Pharma Pricing: Budget Pressures, Value Promises, and Gulf Policy Shifts
Track 3 (Pricing)
Mar 213:20
Conference pass
Retrospective Data as a Proof of Concept for Future Healthcare Sustainability - TBC
Track 10 (Sustainable Access & Policy)
Adam PARNABY, Lead, Global Policy & Access, Bristol Myers Squibb
Mar 213:20
Conference pass
Title TBC
Track 4 (Pre-launch Success)
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Mar 215:10
Conference pass
AI & Digitalization in HTA: Regulation, Transparency and Value
Interactive Panels
Raphael Sonabend-Friend, Associate Director, National Institute for Health and Care Excellence
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Mar 215:10
Conference pass
Financing Advanced Therapeutics: Next-Generation Reimbursement Models
Interactive Panels
Caroline van der Meijden, Director, iMTA
Session led by: 
Laurie Kan, Sr. Director, Global Market Access, CSL
Mar 215:10
Conference pass
From silos to systems: HTA & Pharmaceutical companies & The Trump effect in an ever-changing world - TBC
Interactive Panels
Session led by: 
Mar 215:10
Conference pass
Launching Rare Disease Therapies in Europe and Globally: Aligning Evidence, Pricing, and Access from Day One
Interactive Panels
Moderator: Tomaso Piaggio, Head of International Market Access, Pricing & Policy, Alnylam Pharmaceuticals
Jennifer Quinn, Senior Director, Head of Market Access, Europe and International, Jazz Pharmaceuticals
Lorenzo Capretto, Head of HTA Strategy and Pricing, Global Rare Disease, Chiesi Farmaceutici SpA
Mar 215:10
Conference pass
Market Access Under Pressure: Practical Solutions to Global Policy Shifts like MFN
Interactive Panels
Moderator: Amy Israel, Senior Advisor, Access to Medicines, Union for International Cancer Control
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Anh Bourcet Nguyen, International Director, Government Affairs and Policy, Rare Diseases, AstraZeneca
Mar 215:10
Conference pass
Meaningful patient involvement to improve equity in HTA
Interactive Panels
Mar 215:10
Conference pass
Pre-launch success for orphan diseases in the JCA era - TBC
Interactive Panels
Session led by: 
Mar 215:10
Conference pass
The Value of Joint Scientific Consultation (JSC): Optimizing Trial Design for EU-HTA Success
Interactive Panels
Stephanie Said, Coordination EU HTA Medicinal Products, G-BA
Stine Trolle, Senior Advisor, Danish Medicines Agency (DKMA)
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Mar 215:10
Conference pass
Title TBC
Interactive Panels
Session led by:
Mar 216:25
Conference pass
Chair's opening remarks
Track 1 (Market Access)
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 216:25
Conference pass
Chair's opening remarks
Track 9 (HEOR)
Peter Pemberton-Ross, Head, HE & HTA Strategy, Biogen
Mar 216:25
Conference pass
Chair's opening remarks
Track 6 (Reimbursement)
Adam Gordois, Director, Value Demonstration & HEOR, BioCryst Pharmaceuticals
TRACK 6
Mar 216:25
Conference pass
Chair's remarks
Track 1 (Market Access)
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 216:25
Conference pass
Chair's remarks
Track 7 (Rare Diseases)
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Mar 216:25
Conference pass
Chair's remarks
Track 9 (HEOR)
Peter Pemberton-Ross, Head, HE & HTA Strategy, Biogen
Mar 216:30
Conference pass
Factors impacting GKV rebates for orphan drugs (OD) and the evolution of OD pricing in Germany - TBC
Track 7 (Rare Diseases)
Session led by: 
Mar 216:30
Conference pass
The future of HEOR in HTA: what you need to start doing NOW for improved market access - TBC
Track 1 (Market Access)
Session led by: 
Mar 216:30
Conference pass
The only way is down? Sustaining value through indication expansion - TBC
Track 4 (Pre-launch Success)
Session led by:
Mar 216:30
Conference pass
Trends in HTA and the new launch sequence: market prioritization in a world of changing policies - TBC
Track 2 (HTA)
Session led by: 
Mar 216:50
Conference pass
Deeper payer insights when you need it: How rapid payer research can elevate your market access playbook - TBC
Track 3 (Pricing)
Session led by: 
Mar 217:10
Conference pass
AI in Market Access
Track 8 (Artificial Intelligence & Data)
Mar 217:10
Conference pass
China: risk, threat or opportunity - and for whom?
Track 1 (Market Access)
Neil Grubert, Global Market Access Expert, Independent
Mar 217:10
Conference pass
Germany's new reimbursement policies and the impact on markets
Track 6 (Reimbursement)
Mar 217:10
Conference pass
How to generate robust RWE to inform HTA/Payer Decision-Making
Track 5 (Real World Evidence & Data)
TRACK 5
Mar 217:10
Conference pass
No Green, No Go: How Sustainability is Shifting from a Corporate Responsibility to a Hard Payer Criterion
Track 10 (Sustainable Access & Policy)
Enric Gomez, Director Strategy, Pricing & Analytics, Merck Group
Mar 217:10
Conference pass
No Green, No Go: How Sustainability is Shifting from a Corporate Responsibility to a Hard Payer Criterion
Track 10 (Sustainable Access & Policy)
Enric Gomez, Director Strategy, Pricing & Analytics, Merck Group
Mar 217:10
Conference pass
Policy change impacts on pricing & access of rare disease treatments beyond Europe and US - TBC
Track 7 (Rare Diseases)
Pedro Borga, Global Pricing Director, BioMarin Pharmaceutical Inc.
Mar 217:10
Conference pass
Pricing & reimbursement in an MFN era
Track 3 (Pricing)
Steve Sandor, Vice President, Market Access, Trade and Government Affairs, Paratek Pharmaceuticals , Inc.
Create your personal agenda –check the favourite icon
Mar 38:55
Conference pass
Mar 39:20
Conference pass
Keynote: Beyond the buzzwords: How market access professionals are using AI in practice - TBC
Keynotes
Session led by:
Mar 310:00
Conference pass
Panel: Staying Agile in a Shifting Landscape: Rethinking Global Market Access in the MFN era
Keynotes
How are recent policy developments influencing pricing dynamics and launch sequencing?
Are companies becoming more selective in where and when they launch, and how does this differ for rare & specialty products vs mass-market therapies?
How do you manage pricing risk across interconnected markets without compromising long-term value?
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Marta Andreykiv, VP, Viatris
Moderator: Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Mar 312:15
Conference pass
Chair's opening remarks
Track 1 (Market Access)
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 312:15
Conference pass
Chair's opening remarks
Track 9 (HEOR)
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity BioSciences
Mar 312:20
Conference pass
Disruption or evolution? The high-stakes game of drug pricing - TBC
Track 3 (Pricing)
Session led by:
Mar 312:20
Conference pass
EU JCA: methodological challenges, solutions, and early learnings - TBC
Track 1 (Market Access)
Session led by: 
Mar 312:40
Conference pass
A New AI Framework for NICE Evidence Submission
Track 8 (Artificial Intelligence & Data)
Raphael Sonabend-Friend, Associate Director, National Institute for Health and Care Excellence
Mar 312:40
Conference pass
Building resilient healthcare systems in 2027 and beyond
Track 10 (Sustainable Access & Policy)
Mar 312:40
Conference pass
MFN: Mid to long term implications on market access
Track 1 (Market Access)
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 312:40
Conference pass
Patient Advocacy - The Co-Design of Clinical Endpoints
Track 5 (Real World Evidence & Data)
Andrew Spiegel, CEO, Global Colon Cancer Association
Mar 312:40
Conference pass
Reimbursement landscape in the Netherlands
Track 6 (Reimbursement)
Thomas Broekhoff, Program Manager Medicines, hollandbio
Mar 312:40
Conference pass
The Impact of EU Pharma Legislation: Defining Unmet Medical Need and Breakthroughs
Track 7 (Rare Diseases)
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA & APAC, PTC Therapeutics
Mar 313:00
Conference pass
MFN: why “wait and see” is the most costly strategy - TBC
Track 1 (Market Access)
Session led by: 
Mar 313:20
Conference pass
Comparative pricing in oncology: Germany versus the US – TBC
Track 3 (Pricing)
Joshua Smeltzer, Head of Pricing & Contracting, Market Access Germany, Ipsen Pharma GmbH
Mar 313:20
Conference pass
Developments in access in the US
Track 1 (Market Access)
Mar 313:20
Conference pass
Enriching QoL Measurement with Lived Experience and Patient Preferences: Can It Improve HTA Decisions and How Should It Be Done Robustly
Track 5 (Real World Evidence & Data)
Vidya Breeveld, founder & CEO, Transmineo
Mar 313:20
Conference pass
Finding Synergies in Diagnostics and Pharma to Secure Sustainable Healthcare Budgets - TBC
Track 10 (Sustainable Access & Policy)
Stefaan Fiers, Chapter Head, External Affairs, Roche
Mar 313:20
Conference pass
Reimbursement and Willingness to Pay - TBC
Track 6 (Reimbursement)
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Mar 313:20
Conference pass
The future of AI in market access
Track 8 (Artificial Intelligence & Data)
Marco Rauland, Vice President, Market Access, Strategy, Pricing and Analytics, Merck KGaA
Mar 313:20
Conference pass
Who Counts as Productive? Unpaid Work, Gender Inequality, and Age Bias in HTA
Track 9 (HEOR)
Karla Hernandez-Villafuerte, Senior Researcher, Health Economics, WifOR
Mar 313:20
Conference pass
Why do we have different reimbursement decisions based on similar evidence?
Track 2 (HTA)
Goedele Van Haasteren, Staff Member, Federal Office of Public Health, Switzerland
Mar 315:10
Conference pass
AI in market access: knowing when it’s the hero (and when it isn’t) - TBC
Interactive Panels
Session led by:
Mar 315:10
Conference pass
Critical capabilities for leadership development: stakeholder management & influence
Interactive Panels
Moderator: Natalia Scherff, Leadership Coach, INSEAD, ICF PCC, Coach Scherff
Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Mar 315:10
Conference pass
Health System Readiness for Breakout Medical Devices
Interactive Panels
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Mar 315:10
Conference pass
How EU JCA is shaping Vaccine Reimbursement Pathways
Interactive Panels
Nicolas Jamet, Global Pricing and Market Access Lead, GSK
Anna Vicere, Director, Access Policy & Public Affairs, Vaccines Europe
Mar 315:10
Conference pass
How to Build a Resilient-Launch Strategy
Interactive Panels
- Lessons learnt fromsuccessfullaunches
- Use of digital tools and AI to distinguish critical strategic signals from market noise to drive data-led launch strategies
- Generating the right evidence for productlaunches.
Jolanda Koenders, Head lx, Takeda
Bruno Cherel, Senior Director, Head of Pricing, Jazz Pharmaceuticals
Mar 315:10
Conference pass
Integrating market access into HEOR decisions
Interactive Panels
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity BioSciences
Sophie Janssens, Sr VP, Global Head of Patient Impact Maximization (GO), UCB
Karla Hernandez-Villafuerte, Senior Researcher, Health Economics, WifOR
Luca Luigi Polastri, Global Value and Access Head, Nephrology Franchise, Kyowa Kirin
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Mar 315:10
Conference pass
Lessons learnt from first JCA results, national experiences and comparison of national approaches for pricing & reimbursement decisions
Interactive Panels
Valentina Strammiello, Interim Executive Director, European Patients' Forum
Michal Stanak, Beneluxa Initative
Mar 315:10
Conference pass
Parallel trade, tendering and erosion: pricing across the full product lifecycle and impact of MFN
Interactive Panels
Aveline Godard, Head of Global Pricing & Tendering, Ferring
José Luis Sánchez Chorro, Director, Market Access, Public Affairs, Tenders and Supply, ADVANZ PHARMA
Pedro Borga, Global Pricing Director, BioMarin Pharmaceutical Inc.
Mar 315:10
Conference pass
Securing Fair Pricing and Reimbursement for Value-added Medicines
Interactive Panels
Thomas Grub, Director, Global Pricing and Market Access, Medac GmbH
Marta Andreykiv, VP, Viatris
Klara Marton, International Strategic Business Development Director, Egis Pharmaceuticals Plc
Mar 315:10
Conference pass
The Path to Faster & Sustainable Patient Access in Europe
Interactive Panels
Moderator: Ramiro Gilardino, Associate Professor of Public Health, Buenos Aires School of Public Health
Noem Sain, EU Market Access Lead, UCB Pharma
Alessandro Monaco, General Manager, Oliba Healthcare and Pharma
Mihai Rotaru, Director, Market Access, EFPIA
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Mar 316:50
Conference pass
Pricing negotiation future in Spain
Track 3 (Pricing)
José Luis Sánchez Chorro, Director, Market Access, Public Affairs, Tenders and Supply, ADVANZ PHARMA
Mar 316:50
Conference pass
The missing middle in market access & bridging global strategy with local execution
Track 1 (Market Access)
Manoj Sood, Commercial Access Director, Independent Market Access Expert
last published: 12/Aug/26 11:45 GMT
Get Involved
Sponsorship & Exhibition Sales
Oliver Hersey-Swan
oliver.hersey-swan@terrapinn.com
Speaking Opportunities
Isla Sutherland
isla.sutherland@terrapinn.com
Marketing Opportunities
Hidy Lee
hidy.lee@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events